SteadyMed to Present at the Annual Ladenburg Thalmann 2016 Healthcare Conference
September 20 2016 - 8:30AM
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company
focused on the development of drug product candidates to treat
orphan and high-value diseases with unmet parenteral delivery
needs, today announced that Jonathan Rigby, President and Chief
Executive Officer, will present at the Annual Ladenburg Thalmann
Healthcare Conference, being held on September 27, 2016 at The
Sofitel, in New York City. During the presentation, Mr. Rigby will
provide an overview and update on the company's business.
Date: Tuesday, September 27, 2016Time: 9:30 AM
ET
A live audio webcast and archive of the
presentation will be available through the Events and Presentations
page of the company's corporate website (www.steadymed.com).
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical
company focused on the development of drug products to treat orphan
and high value diseases with unmet parenteral delivery needs. The
company's lead drug product candidate is Trevyent®, a development
stage drug product that combines SteadyMed's PatchPump® technology
with treprostinil, a vasodilatory prostacyclin analogue to treat
pulmonary arterial hypertension (PAH). SteadyMed intends to
commercialize Trevyent in the U.S. and has signed an exclusive
license and supply agreement with Cardiome Pharma Corp. for the
commercialization of Trevyent in Europe, Canada and the Middle
East. SteadyMed has offices in San Ramon, California and Rehovot,
Israel. For additional information about SteadyMed please visit
www.steadymed.com.
Marylyn Rigby
Senior Director, Investor Relations and Marketing
925-272-4999
mrigby@steadymed.com
The Ruth Group
David Burke
(646) 536-7009
dburke@theruthgroup.com
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Apr 2023 to Apr 2024